Latest news with #BayerCropScience
Mint
4 days ago
- Business
- Mint
Canara Bank to Hero MotoCorp: Eight stocks to buy for up to 15% gains on robust monsoon, strong Indian economy
The Indian stock market benchmark indices, Sensex and Nifty 50, extended rally for the third consecutive month in May. Nifty 50 has gained 1.7% this month, underpinned by easing tariff concerns, positive developments in India–US trade negotiations, and a rebound in Foreign Institutional Investor (FII) inflows The next key trigger for the Indian stock market would be the monsoon season. According to the India Meteorological Department (IMD) India is likely to experience above average monsoon rains in 2025. This projection signals a potentially fruitful agriculture season which is crucial for rural demand and benefit sectors like agrochemicals, fertilizers, tractors, two-wheelers and FMCG. Green shoots of recovery in rural markets, sustained momentum in manufacturing and services sectors augur well for consumption demand in the near term, analysts said. 'Steadily improving macros like resilient GDP growth, down trending inflation and interest rates and declining fiscal and current account deficits lay the foundation for a strong economy and earnings recovery in the medium term. Investors should remain invested and buy quality stocks on dips,' said VK Vijayakumar, Chief Investment Strategist, Geojit Investments. Meanwhile, brokerage firm Way2Wealth has released the list of Monsoon stock picks. The stocks are believed to gain from improving rural liquidity and demand on the back of better monsoon. It believes these quality stocks have strong fundamentals and a positive correlation to monsoon trends and other key macroeconomic indicators. The brokerage firm suggests these stocks to buy for a time horizon of 6-8 months. These stocks to buy include Bayer CropScience, Canara Bank, Coromandel International, Emami, Godrej Agrovet, Hero MotoCorp, Supreme Industries and Swaraj Engines. Here are the Monsoon stock picks by Way2Wealth: Bayer CropScience is expected to maintain a revenue, EBITDA and PAT CAGR of 10%, 30% and 28% over FY25–27E, respectively. At the CMP, Bayer CropScience share price is trading at a P/E of 28x and an EV/EBITDA of 21x based on FY27E estimates, Way2Wealth said. The brokerage firm assigns a 'Buy' rating to Way2Wealth shares with a target price of ₹ 6,450 apiece. Canara Bank's balance sheet stands strong with CRAR at 16.3%. It will be further strengthened with IPO proceeds of Canara Robeco which will provide growth capital to the bank, said the brokerage firm. It has a 'Buy' call on Canara Bank shares with a target price of ₹ 125. Coromandel International is progressing with key projects, targeting commissioning by FY26–27. It is focusing on capex realignment, backward integration, and new product growth such as Nano DAP, while maintaining a revenue, EBITDA and PAT CAGR of 9%, 22% and 17% over FY25-27E, respectively. At the CMP, Coromandel International shares are trading at a P/E of 25x and an EV/EBITDA of 17x based on FY27E estimates. Way2Wealth assigns a 'Buy' rating to Coromandel International shares, with a target price of ₹ 2,700 apiece. Emami remains committed to grow through various initiatives like newer launches, expanded reach and increased digital presence through e-commerce channels despite high inflationary environment and urban slowdown. Further, it has a strong presence in the niche personal care categories, with low penetration. At CMP, Emami stock is trading at 27x its FY26 P/E . The brokerage firm recommends a 'Buy' call on Emami shares based on its strong fundamentals. It has Emami share price target of ₹ 660 apiece. Godrej Agrovet's diversified products across less regulated agricultural inputs and outputs, leading market positions across all of them and high-quality management and parentage, makes it a proxy to ride the theme of Indian agriculture, said the brokerage firm. The company has a strong Balance Sheet and generates healthy cash flows and return ratios. At CMP, Godrej Agrovet stock price is trading at 28x its FY26 P/E. The brokerage has a 'Buy' call on the stock with a target of ₹ 840 level. Way2Wealth remains optimistic about growth of the company in the near term. The company currently trades at a P/E 15.9x on FY27E below its 5-year average P/E of 21.6x. It has a 'Buy' rating and Hero MotoCorp share price target of ₹ 5,000 A recovery in plumbing demand is anticipated as channel inventories stabilize and government spending picks up, the brokerage firm said as it remains optimistic about growth of the company in near term. Supreme Industries shares currently trade at a P/E 39.7x on FY27E below its 5-year Average PE of 42.2x. The brokerage recommends buying Supreme Industries shares for a target price of ₹ 4,750 apiece. The company's engine business is likely to move in tandem with industry. Further, return ratios (RoCE: ~53+%, RoE: ~40%) along with positive FCF generation will also be among the key triggers, said the broking house. At CMP, Swaraj Engines share price is trading at 26x its FY26 P/E. It recommends buying Swaraj Engines shares for a target price of ₹ 4,600 apiece. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
7 days ago
- Business
- Business Standard
Bayer CropScience standalone net profit rises 49.27% in the March 2025 quarter
Sales rise 32.07% to Rs 1046.40 crore Net profit of Bayer CropScience rose 49.27% to Rs 143.30 crore in the quarter ended March 2025 as against Rs 96.00 crore during the previous quarter ended March 2024. Sales rose 32.07% to Rs 1046.40 crore in the quarter ended March 2025 as against Rs 792.30 crore during the previous quarter ended March 2024. For the full year,net profit declined 23.30% to Rs 568.00 crore in the year ended March 2025 as against Rs 740.50 crore during the previous year ended March 2024. Sales rose 7.19% to Rs 5473.40 crore in the year ended March 2025 as against Rs 5106.20 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1046.40792.30 32 5473.405106.20 7 OPM % 16.3212.29 - 12.6018.74 - PBDT 202.20121.30 67 792.301015.40 -22 PBT 167.90105.40 59 707.40941.40 -25 NP 143.3096.00 49 568.00740.50 -23
Economic Times
7 days ago
- Business
- Economic Times
Bayer CropScience shares soar 13% as Q4 profit jumps 49% YoY; board declares Rs 35 dividend
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Bayer CropScience zoomed 13% to an intraday high of Rs 5,792 on the BSE on Tuesday after strong financial performance in Q4. The company reported a 49% YoY jump in its PAT for Q4FY25 at Rs 143.30 crore, while also announcing a dividend of Rs 35 per net profit for the corresponding quarter of the previous financial year stood at Rs 96 the company's board has recommended a dividend of Rs 35 per share for eligible shareholders. The details regarding the record and payout date for the same have not yet been provided by the company registered its revenue from operations for the quarter under review at Rs 1,046.4 crore, up from Rs 792.3 crore in the year-ago FY 2024-25, Bayer CropScience's revenue from operations increased to Rs 5473.4 crore, compared to Rs 5106.2 crore in the previous year."Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer's reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs,' said Vinit Jindal, Executive Director and Chief Financial Officer of Bayer CropScience, while commenting on the Q4 is a global enterprise with core competencies in the life science fields of health care and nutrition. It is engaged in the Agri Care business, which primarily includes the manufacture, sale and distribution of insecticides, fungicides, herbicides and various other agrochemical products and corn seeds.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
7 days ago
- Business
- Time of India
Bayer CropScience shares soar 13% as Q4 profit jumps 49% YoY; board declares Rs 35 dividend
Shares of Bayer CropScience zoomed 13% to an intraday high of Rs 5,792 on the BSE on Tuesday after strong financial performance in Q4. The company reported a 49% YoY jump in its PAT for Q4FY25 at Rs 143.30 crore, while also announcing a dividend of Rs 35 per share. The net profit for the corresponding quarter of the previous financial year stood at Rs 96 crore. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Soacha: Deja que la IA guíe tu trading con CFD y aumenta tus ingresos extra. Trade AI Registrarse Undo Further, the company's board has recommended a dividend of Rs 35 per share for eligible shareholders. The details regarding the record and payout date for the same have not yet been provided by the company. The company registered its revenue from operations for the quarter under review at Rs 1,046.4 crore, up from Rs 792.3 crore in the year-ago period. For FY 2024-25, Bayer CropScience's revenue from operations increased to Rs 5473.4 crore, compared to Rs 5106.2 crore in the previous year. Live Events "Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer's reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs,' said Vinit Jindal, Executive Director and Chief Financial Officer of Bayer CropScience, while commenting on the Q4 results. Also read: Olectra Greentech shares tank 13% as Maha gov reportedly cancels big e-bus order Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. It is engaged in the Agri Care business, which primarily includes the manufacture, sale and distribution of insecticides, fungicides, herbicides and various other agrochemical products and corn seeds.
Business Standard
7 days ago
- Business
- Business Standard
Bayer CropScience spurts after Q4 PAT rises 49% YoY
Bayer CropScience surged 11.58% to Rs 5724 after the company's standalone net profit jumped 49.27% to Rs 143.30 crore while net sales rose 32.07% to Rs 1,046.40 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 167.90 crore in Q4 FY25, up 399.70% quarter-on-quarter, and 59.30% year-on-year. However, the company's standalone net profit surged 319.01% while net sales declined 1.04% in Q4 March 2025 over Q3 December 2024. For the full year, net profit fell 23.30% to Rs 568 crore while net sales rose 7.19% to Rs 5,473.40 crore in the year ended March 2025 over the year ended March 2024. PBT declined 24.86% year-on-year to Rs 707.40 crore in FY25 over FY24. The company's standalone net cash from operating activities stood at Rs 262 crore in FY25, lower than Rs 951.60 crore in FY24. Commenting on the quarterly results, Simon Wiebusch, vice chairman, managing director and CEO, Bayer CropScience said, "In Q4, our revenue from Operations grew by 32 percent over the previous year, driven by strong performance in spring corn and by both strong performance and double-digit liquidation growth in the crop protection portfolio. The promotional investments made in the previous quarter generated significant returns. Quarter-on-quarter deviations reflect the realities of our agriculture. Our focus on liquidation-led channel management aligns with market realities and demonstrates our commitment to delivering continuous value." Speaking on the FY results, Vinit Jindal, executive director and chief financial officer, Bayer CropScience, said, "Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayers reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs." The board has recommended a final dividend payment of Rs 35 per equity share for the financial year ended March 31, 2025, subject to shareholders approval. Bayer CropScience is engaged in 'agri care' business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products.
